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Fig I-Model patient pathways 
 
Appendix Fig I- Patient flow model summary
 
Appendix Fig II- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 25% 
Decision Rule versus treat no one strategy 
 
Appendix Fig III- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 
22.5% Decision Rule versus treat no one strategy 
 
  
Appendix Fig IV- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 20% 
Decision Rule versus treat no one strategy 
 
 
Appendix Fig V- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 
17.5% Decision Rule versus treat no one strategy 
 
  
Appendix Fig VI- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 15% 
Decision Rule versus treat no one strategy 
 
Appendix Fig VII- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 
12.5% Decision Rule versus treat no one strategy 
 
  
Appendix Fig VIII- Probabilistic Sensitivity Analysis Scatterplot of incremental costs and effects of 
10% Decision Rule versus treat no one strategy 
 
 
Appendix Fig IX Cost Effectiveness Acceptability Curve of Treat No one versus 17.5% Decision Rule 
 
  
Appendix Fig X Cost Effectiveness Acceptability Curve of 25% Decision Rule versus 17.5% Decision 
Rule 
 
Appendix Fig XI Cost Effectiveness Acceptability Curve of 22.5% Decision Rule versus 17.5% Decision 
Rule 
 
  
Appendix Fig XII Cost Effectiveness Acceptability Curve of 20% Decision Rule versus 17.5% Decision 
Rule 
 
Appendix Fig XIII Cost Effectiveness Acceptability Curve of 15% Decision Rule versus 17.5% Decision 
Rule 
 
  
Appendix Fig XIV Cost Effectiveness Acceptability Curve of 12.5% Decision Rule versus 17.5% 
Decision Rule 
 
Appendix Fig XV Cost Effectiveness Acceptability Curve of 10% Decision Rule versus 17.5% Decision 
Rule 
 
